26 de novo renal transplant recipients (13 males, 13 females) of mean age 41 years, in whom particularly chronic glomerulonephritis was diagnosed, participated in the clinical trial evaluating the efficacy and safety of oral cyclosporine capsules Consupren during 6-month therapy. Together with cyclosporine, all patients received prednisolone and azathioprine. Health status and outcomes from the patient’s point of view were evaluated by the SF-36 (36-Item Short Form health survey). Three evaluations of the SF-36 were studied: prior to study treatment, at 1 and 6 months. The scores were compared with published norms for the general population. Except for bodily pain, the scores in all scales of the SF-36 improved significantly during the first month. Patients receiving Consupren during 6 months had significantly higher scores on all except perception of general and mental health dimensions. In these cases differences were near significant values (p=0.055 and p=0.057 respectively). However, after the transformation to the norms for the general population, the SF-36 scores observed at 1 and 6 months are in the range of normative values. Patients had the summary SF-36 score on mental health in comparison with that of physical health significantly better at 1 month; however after 6-month therapy the SF-36 scores of both dimensions were significantly improved. The quality of life evaluated by the SF-36 in de novo patients after renal transplantation receiving Consupren is comparable to norms published for the general population.